A Phase 3 interventional study of niacin extended-release (NER) and aspirin (ASA) in Dyslipidemia, sponsored by Abbott. Completed at 26 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-09-02.
Sponsored by Abbott · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Dyslipidemias by Abbott — none open to participants now, none under way, none of them phase 3. Dyslipidemias · Abbott.
Among the 22 studies in Dyslipidemias by Abbott, this one is the 13th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2008, is one of 15 in phase 3, and was the 15th registered.
1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.
Browse Dyslipidemias studies →None of the 22 studies in Dyslipidemias by Abbott is open now. The open studies under Dyslipidemias, anywhere →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 17 · Phase 4 2
First in 2004; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 277 is above the median of 100 across 986 interventional studies indexed under Dyslipidemias.
Median enrollment 382 across the 19 interventional studies, 172 across the 2 observational. Of the 22 that completed or were terminated, 11 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 22 studies in Dyslipidemias by Abbott, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study was to assess the effect of aspirin (ASA) on niacin extended-release (NER)-induced flushing in subjects with dyslipidemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Aspirin (ASA) daily during run-in (1 week); ASA 30 min prior to niacin extended-release (\[NER\], 500 mg starting dose), daily during coadministration period (4 weeks)
Drug: niacin extended-release (NER) · Drug: aspirin (ASA)
Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA 30 min prior to niacin extended-release (\[NER\], 500 mg starting dose), daily during coadministration period (4 weeks)
Drug: niacin extended-release (NER) · Drug: aspirin (ASA) · Drug: aspirin placebo (ASA Pbo)
Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA Pbo 30 min prior to niacin extended-release (\[NER\], 500 mg starting dose), daily during coadministration period (4 weeks)
Drug: niacin extended-release (NER) · Drug: aspirin placebo (ASA Pbo)
Aspirin (ASA) daily during run-in (1 week); ASA 30 min prior to niacin extended-release (\[NER\], 1000 mg starting dose), daily during coadministration period (4 weeks)
Drug: niacin extended-release (NER) · Drug: aspirin (ASA)
Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA 30 min prior to niacin extended-release (\[NER\], 1000 mg starting dose), daily during coadministration period (4 weeks)
Drug: niacin extended-release (NER) · Drug: aspirin (ASA) · Drug: aspirin placebo (ASA Pbo)
Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA Pbo 30 min prior to niacin extended-release (\[NER\], 1000 mg starting dose), daily during coadministration period (4 weeks)
Drug: niacin extended-release (NER) · Drug: aspirin placebo (ASA Pbo)
Tablets administered once daily; titrated to 2000 mg maximum dose during coadministration period
Also known as: Niaspan
325 mg tablets administered once daily
Also known as: acetylsalicylic acid
Tablets administered once daily
Also known as: placebo
Maximum Severity of Flushing Events During Week 1 of Niacin Extended-release (NER) Treatment
The maximum severity of flushing events subjects experienced during Week 1 of NER treatment was categorized as none, mild, moderate, severe, or very severe using the Flushing Assessment Tool via an e-diary. Flushing was assessed daily and the percentage of subjects with maximum flushing severity in each category was calculated.
Time frame: From Baseline to end of Week 1
Maximum Severity of Flushing Events Overall During 4 Weeks of Niacin Extended-release (NER) Treatment
The maximum severity of flushing events subjects experienced during 4 weeks of NER treatment was categorized as none, mild, moderate, severe, or very severe using the Flushing Assessment Tool via an e-diary. Flushing was assessed daily and the percentage of subjects with maximum flushing severity in each category was calculated.
Time frame: 4 weeks
Mean of Maximum Severity of Flushing Events Overall During 4 Weeks of Niacin Extended-release (NER) Treatment
Subjects assessed the severity of flushing events on a 10-point numeric rating scale of 1-3 (mild), 4-6 (moderate), 7-9 (severe), and 10 (very severe) using the Flushing Assessment Tool via an e-diary. For subjects who did not experience flushing, a score of 0 was assigned. Flushing was assessed daily.
Time frame: 4 weeks
Mean Number of Moderate or Greater Flushing Events Per Subject Per Week Overall During 4 Weeks of Niacin Extended-release (NER) Treatment
Flushing was assessed daily using the Flushing Assessment Tool via an e-diary and the mean number of flushing events per subject per week considered moderate or greater in severity was calculated. Flushing events were rated by the subject using a categorical scale of mild, moderate, severe, or very severe.
Time frame: 4 weeks
Participants were enrolled at 47 study sites in the United States between February and April, 2008.
| Milestone | NER 500; ASA run-in, ASA Coadmin | NER 500; ASA Pbo run-in, ASA Coadmin | NER 500; ASA Pbo run-in, ASA Pbo Coadmin | NER 1000; ASA run-in; ASA Coadmin | NER 1000; ASA Pbo run-in, ASA Coadmin | NER 1000; ASA Pbo run-in, ASA Pbo Coadmin |
|---|---|---|---|---|---|---|
| Started | 45 | 44 | 44 | 44 | 45 | 45 |
| Completed | 44 | 43 | 41 | 43 | 41 | 44 |
| Not completed | 1 | 1 | 3 | 1 | 4 | 1 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 1 | 3 | 1 |
| Withdrew: Noncompliance | 1 | 0 | 1 | 0 | 0 | 0 |
| Milestone | NER 500; ASA run-in, ASA Coadmin | NER 500; ASA Pbo run-in, ASA Coadmin | NER 500; ASA Pbo run-in, ASA Pbo Coadmin | NER 1000; ASA run-in; ASA Coadmin | NER 1000; ASA Pbo run-in, ASA Coadmin | NER 1000; ASA Pbo run-in, ASA Pbo Coadmin |
|---|---|---|---|---|---|---|
| Started | 44 | 43 | 41 | 43 | 41 | 44 |
| Completed | 40 | 38 | 31 | 36 | 36 | 38 |
| Not completed | 4 | 5 | 10 | 7 | 5 | 6 |
| Withdrew: Adverse event | 3 | 1 | 7 | 4 | 3 | 4 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 1 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 1 | 1 | 0 |
| Withdrew: Other | 0 | 2 | 3 | 1 | 1 | 1 |
The maximum severity of flushing events subjects experienced during Week 1 of NER treatment was categorized as none, mild, moderate, severe, or very severe using the Flushing Assessment Tool via an e-diary. Flushing was assessed daily and the percentage of subjects with maximum flushing severity in each category was calculated.
| Percentage of Subjects | Any Acetylsalicylic Acid | No Acetylsalicylic Acid |
|---|---|---|
| None | 57 | 48 |
| Mild | 28 | 24 |
| None/mild | 85 | 71 |
| Moderate | 11 | 17 |
| Severe | 4 | 8 |
| Very severe | 1 | 4 |
The maximum severity of flushing events subjects experienced during 4 weeks of NER treatment was categorized as none, mild, moderate, severe, or very severe using the Flushing Assessment Tool via an e-diary. Flushing was assessed daily and the percentage of subjects with maximum flushing severity in each category was calculated.
| Percentage of Subjects | Any Acetylsalicylic Acid | No Acetylsalicylic Acid |
|---|---|---|
| None | 30 | 15 |
| Mild | 28 | 14 |
| None/Mild | 58 | 30 |
| Moderate | 28 | 35 |
| Severe | 11 | 23 |
| Very severe | 4 | 13 |
Subjects assessed the severity of flushing events on a 10-point numeric rating scale of 1-3 (mild), 4-6 (moderate), 7-9 (severe), and 10 (very severe) using the Flushing Assessment Tool via an e-diary. For subjects who did not experience flushing, a score of 0 was assigned. Flushing was assessed daily.
| Scores on a Scale | Any Acetylsalicylic Acid | No Acetylsalicylic Acid |
|---|---|---|
| Mean of Maximum Severity of Flushing Events Overall During 4 Weeks of Niacin Extended-release (NER) Treatment | 3.1 ± 2.86 | 5.1 ± 3.16 |
Flushing was assessed daily using the Flushing Assessment Tool via an e-diary and the mean number of flushing events per subject per week considered moderate or greater in severity was calculated. Flushing events were rated by the subject using a categorical scale of mild, moderate, severe, or very severe.
| Number of Events per Subject per Week | Any Acetylsalicylic Acid | No Acetylsalicylic Acid |
|---|---|---|
| Mean Number of Moderate or Greater Flushing Events Per Subject Per Week Overall During 4 Weeks of Niacin Extended-release (NER) Treatment | 0.3 ± 0.64 | 0.8 ± 1.10 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Any Acetylsalicylic Acid | — | — | — |
| No Acetylsalicylic Acid | — | — | — |
| Event | Any Acetylsalicylic Acid | No Acetylsalicylic Acid |
|---|---|---|
| Esophageal ulcerGastrointestinal disorders | 0/171 | 1/85 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 1/171 | 0/85 |
| Event | Any Acetylsalicylic Acid | No Acetylsalicylic Acid |
|---|---|---|
| FlushingVascular disorders | 117/171 | 71/85 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/171 | 3/85 |
| Non-cardiac chest painGeneral disorders | 1/171 | 2/85 |
| Blood creatine phosphokinase increasedInvestigations | 0/171 | 2/85 |
| Blood uric acid increasedInvestigations | 0/171 | 2/85 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/171 | 2/85 |
| RashSkin and subcutaneous tissue disorders | 3/171 | 2/85 |
| NauseaGastrointestinal disorders | 4/171 | 1/85 |
| Age Continuous(Years) | NER 500; ASA run-in, ASA Coadmin | NER 500; ASA Pbo run-in, ASA Coadmin | NER 500; ASA Pbo run-in, ASA Pbo Coadmin | NER 1000; ASA run-in, ASA Coadmin | NER 1000; ASA Pbo run-in, ASA Coadmin | NER 1000; ASA Pbo run-in, ASA Pbo Coadmin | Total |
|---|---|---|---|---|---|---|---|
| Mean | 55.5 ± 10.62 | 49.0 ± 10.48 | 51.5 ± 12.58 | 53.7 ± 12.4 | 54.8 ± 11.08 | 52.3 ± 12.45 | 52.8 ± 11.73 |
| Sex: Female, Male(Participants) | NER 500; ASA run-in, ASA Coadmin | NER 500; ASA Pbo run-in, ASA Coadmin | NER 500; ASA Pbo run-in, ASA Pbo Coadmin | NER 1000; ASA run-in, ASA Coadmin | NER 1000; ASA Pbo run-in, ASA Coadmin | NER 1000; ASA Pbo run-in, ASA Pbo Coadmin | Total |
|---|---|---|---|---|---|---|---|
| Female | 21 | 23 | 21 | 15 | 21 | 23 | 124.0 |
| Male | 23 | 20 | 20 | 28 | 20 | 21 | 132.0 |
| Region of Enrollment(participants) | NER 500; ASA run-in, ASA Coadmin | NER 500; ASA Pbo run-in, ASA Coadmin | NER 500; ASA Pbo run-in, ASA Pbo Coadmin | NER 1000; ASA run-in, ASA Coadmin | NER 1000; ASA Pbo run-in, ASA Coadmin | NER 1000; ASA Pbo run-in, ASA Pbo Coadmin | Total |
|---|---|---|---|---|---|---|---|
| United States | 44 | 43 | 41 | 43 | 41 | 44 | 256.0 |
The record gives a start of Feb 2008, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2009, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aspirin